Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.

Niitsu N, Okamoto M, Tamaru JI, Yoshino T, Nakamura N, Nakamura S, Ohshima K, Nakamine H, Hirano M.

Ann Oncol. 2010 Oct;21(10):2069-74. doi: 10.1093/annonc/mdq057. Epub 2010 Mar 15.

PMID:
20231297
2.

The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.

Hyo R, Tomita N, Takeuchi K, Aoshima T, Fujita A, Kuwabara H, Hashimoto C, Takemura S, Taguchi J, Sakai R, Fujita H, Fujisawa S, Ogawa K, Motomura S, Suzuki R, Ishigatsubo Y.

Hematol Oncol. 2010 Mar;28(1):27-32. doi: 10.1002/hon.896.

PMID:
19358143
3.

CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab.

Miyazaki K, Yamaguchi M, Suzuki R, Kobayashi Y, Maeshima AM, Niitsu N, Ennishi D, Tamaru JI, Ishizawa K, Kashimura M, Kagami Y, Sunami K, Yamane H, Nishikori M, Kosugi H, Yujiri T, Hyo R, Katayama N, Kinoshita T, Nakamura S.

Ann Oncol. 2011 Jul;22(7):1601-7. doi: 10.1093/annonc/mdq627. Epub 2011 Jan 3.

PMID:
21199885
4.

A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.

Niitsu N, Tamaru J, Yoshino T, Nakamura N, Nakamura S, Ohshima K, Nakamine H, Okamoto M.

Ann Hematol. 2011 Feb;90(2):185-92. doi: 10.1007/s00277-010-1060-8. Epub 2010 Sep 1.

PMID:
20809421
5.

CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.

Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y, Takahashi S, Komatsu H, Ikeda K, Yamaguchi M, Suzuki R, Tanimoto M, Hatake K.

Ann Oncol. 2008 Nov;19(11):1921-6. doi: 10.1093/annonc/mdn392. Epub 2008 Jun 23.

PMID:
18573805
6.

Recent advances in de novo CD5+ diffuse large B cell lymphoma.

Jain P, Fayad LE, Rosenwald A, Young KH, O'Brien S.

Am J Hematol. 2013 Sep;88(9):798-802. doi: 10.1002/ajh.23467. Epub 2013 Jun 5. Review.

7.

Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.

Yhim HY, Kim JS, Kang HJ, Kim SJ, Kim WS, Choi CW, Eom HS, Kim JA, Lee JH, Won JH, Shim H, Huh J, Lee DH, Suh C, Kwak JY.

Int J Cancer. 2012 Jul 1;131(1):235-43. doi: 10.1002/ijc.26352. Epub 2011 Aug 30.

8.

Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy.

Song MK, Chung JS, Seol YM, Kim SG, Shin HJ, Choi YJ, Cho GJ, Shin DH.

Ann Oncol. 2010 Jan;21(1):140-4. doi: 10.1093/annonc/mdp505. Epub 2009 Nov 3.

PMID:
19887468
9.

[Clinical analysis of 10 patients with de novo CD5 positive diffuse large B cell lymphoma].

Zhang Q, Zhang HY, Zhong FL, Zhang WL, Xu L, Feng J, Meng QX.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Apr;21(2):399-402. doi: 10.7534/j.issn.1009-2137.2013.02.029. Chinese.

PMID:
23628041
10.

Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.

Tanaka T, Shimada K, Yamamoto K, Hirooka Y, Niwa Y, Sugiura I, Kitamura K, Kosugi H, Kinoshita T, Goto H, Nakamura S.

Ann Hematol. 2012 Mar;91(3):383-90. doi: 10.1007/s00277-011-1306-0. Epub 2011 Aug 6.

PMID:
21822617
11.

[CD5 expression is an adverse prognostic factor in diffuse large B-cell lymphoma].

Zheng Y, Ma XB, Jiang J, Wang YP.

Zhonghua Bing Li Xue Za Zhi. 2012 Mar;41(3):156-60. doi: 10.3760/cma.j.issn.0529-5807.2012.03.003. Chinese.

PMID:
22800477
12.

Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.

Thakral B, Medeiros LJ, Desai P, Lin P, Yin CC, Tang G, Khoury JD, Hu S, Xu J, Loghavi S, Hu B, Oki Y, Li S.

Eur J Haematol. 2017 Apr;98(4):415-421. doi: 10.1111/ejh.12847. Epub 2017 Jan 30.

PMID:
28039906
13.

Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.

Belotti A, Doni E, Bolis S, Rossini F, Casaroli I, Pezzatti S, Pogliani EM, Pioltelli PE.

Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):208-13. doi: 10.1016/j.clml.2014.10.001. Epub 2014 Oct 23.

PMID:
25468321
14.

Diffuse large B-cell lymphoma of the orbit: clinicopathologic, immunohistochemical, and prognostic features of 20 cases.

Stacy RC, Jakobiec FA, Herwig MC, Schoenfield L, Singh A, Grossniklaus HE.

Am J Ophthalmol. 2012 Jul;154(1):87-98.e1. doi: 10.1016/j.ajo.2012.01.021. Epub 2012 Apr 13.

PMID:
22503694
15.

A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.

Li X, Xia B, Guo S, Zhan Z, Zhang L, Zhao D, Wu X, Zhang Y.

Ann Hematol. 2013 Jun;92(6):807-15. doi: 10.1007/s00277-013-1701-9. Epub 2013 Feb 17.

PMID:
23417758
16.

R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma.

He XH, Li B, Yang S, Lu N, Zhang X, Zou SM, Li YX, Song YW, Zheng S, Dong M, Zhou SY, Yang JL, Liu P, Zhang CG, Qin Y, Feng FY, Shi YK.

Chin J Cancer. 2012 Jun;31(6):306-14. doi: 10.5732/cjc.011.10420. Epub 2012 May 23.

17.

MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma.

Kojima M, Nishikii H, Takizawa J, Aoki S, Noguchi M, Chiba S, Ando K, Nakamura N.

Leuk Lymphoma. 2013 Oct;54(10):2149-54. doi: 10.3109/10428194.2013.771398. Epub 2013 Mar 8.

PMID:
23363269
19.

[Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].

Yao WK, Wang YP, Peng F, Zheng Y, Zou YB, Gao JN, Liu XL.

Zhonghua Bing Li Xue Za Zhi. 2012 Dec;41(12):818-22. doi: 10.3760/cma.j.issn.0529-5807.2012.12.006. Chinese.

PMID:
23324230
20.

Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.

Tsuyama N, Ennishi D, Yokoyama M, Baba S, Asaka R, Mishima Y, Terui Y, Hatake K, Takeuchi K.

Oncotarget. 2017 May 16;8(20):33487-33500. doi: 10.18632/oncotarget.16532.

Supplemental Content

Support Center